Bedaquiline: a review of human pharmacokinetics and drug-drug interactions
| Autor: | R. P. G. van Heeswijk, Brian Dannemann, Richard M. W. Hoetelmans |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Microbiology (medical)
Efavirenz Nevirapine Antifungal Agents Antitubercular Agents Pharmacology Antiviral Agents chemistry.chemical_compound Clinical Trials Phase II as Topic Tuberculosis Multidrug-Resistant medicine Humans Pharmacology (medical) Drug Interactions Diarylquinolines Ethambutol Clinical Trials Phase I as Topic business.industry Lopinavir Pyrazinamide Rifapentine Infectious Diseases chemistry Ritonavir Bedaquiline business medicine.drug |
| Zdroj: | The Journal of antimicrobial chemotherapy. 69(9) |
| ISSN: | 1460-2091 |
| Popis: | Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|